Skip to content

Metabolic

Dulaglutide

Also called Trulicity

InjectableEvidence AOnce a week
Half-life
113hours
Typical vial
3 / 4.5mg
Research amounts
0.75–4.5mg

per administration

Common schedule
Once a week
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Licensed as a medicine in the US and EU.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded75units dialled
Concentration
1mg/mL
Volume per draw
0.75mL
Units to dial
75
Doses per cartridge
4

This is 75 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Dulaglutide describe 0.754.5 mg per administration. Descriptive only, not a recommendation.

About 4.7 days. Built as a GLP-1 analog fused to a modified IgG4 Fc fragment, which is what stretches elimination to several days and supports once-weekly dosing.

Dosing schedule

How Dulaglutide is commonly stepped up, for reference only.

These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.

PhaseAmountFrequencyRoute
Weeks 1–4Starting step.0.75 mgOnce weeklySubQ
Weeks 5+1.5 mgOnce weeklySubQ
After ≥4 weeks3 mgOnce weeklySubQ
After ≥4 more weeksHighest step in AWARD-11; step up no sooner than every 4 weeks.4.5 mgOnce weeklySubQ

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak
1.49× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
23.5days

About five half-lives

Administrations
1/ week

Where these numbers come from

  • AWARD-11 (Frías JP et al., Diabetes Care 2021;44:765)Once-weekly dulaglutide 3.0 mg and 4.5 mg compared with 1.5 mg over 52 weeks in adults with type-2 diabetes.

Next steps